# A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

> **NCT05602025** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 140 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Depemokimab

## Key facts

- **NCT ID:** NCT05602025
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-13
- **Primary completion:** 2023-10-23
- **Final completion:** 2023-10-23
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2024-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05602025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05602025, "A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05602025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*